Comparative Immune Response after Vaccination with SOBERANA® 02 and SOBERANA® plus Heterologous Scheme and Natural Infection in Young Children
Heterologous
Memory T cell
DOI:
10.20944/preprints202309.0564.v1
Publication Date:
2023-09-12T02:52:11Z
AUTHORS (16)
ABSTRACT
(1) Background: SARS-CoV-2 infection is mostly accompanied by mild COVID-19 symptoms in children. However, the multisystem inflammatory syndrome (MIS-C) and long-term sequelae are often severe complications. Therefore, protection of pediatric population against with effective vaccines particularly important. Here we compare humoral cellular immune responses elicited children (n=15) aged 5-11 years vaccinated RBD-based combined a heterologous scheme SOBERANA® 02 Plus those from (n=10) 4-11 who recovered symptomatic COVID-19. (2) Methods: Blood samples were taken 14 days after last dose for 45-60 diagnosis Anti-RBD IgG ACE2-RBD inhibition assessed ELISA; IgA, cytokine cytotoxic related proteins profile determined multiplex assays. Total B T cell subpopulations IFN-γ release measured multiparametric flow cytometry using large panel antibodies vitro stimulation S1 peptides. (3) Results: Significant higher levels specific anti-RBD IgA capacity found comparison to Th1-like Th2-like CD4+ cells also significantly subjects. secretion central memory children, but no differences between both groups CD8+ effector, terminal naïve subpopulations. High IL-2, IL-6, IL-10 contrast low IL-4 suggesting predominant Th1 polarization. Cytotoxic-related granzyme A B, perforin granulin supernatant (4) Conclusions: Vaccination 02/ induces strong antibody response compared natural infections young
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....